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Background: There is no consensus on the most effective strategy (mammography or magnetic resonance imaging (MRI)) for
screening women with BRCA1 or BRCA2 mutations. The effectiveness and cost-effectiveness of the Dutch, UK and US screening
strategies, which involve mammography and MRI at different ages and intervals were evaluated in high-risk women with BRCA1 or
BRCA2 mutations.
Methods: Into a validated simulation screening model, outcomes and cost parameters were integrated from published and
cancer registry data. Main outcomes were life-years gained and incremental cost-effectiveness ratios. The simulation was situated
in the Netherlands as well as in the United Kingdom, comparing the Dutch, UK and US strategies with the population screening as
a reference. A discount rate of 3% was applied to both costs and health benefits.
Results: In terms of life-years gained, the strategies from least to most cost-effective were the UK, Dutch and US screening
strategy, respectively. However, the differences were small. Applying the US strategy in the Netherlands, the costs were h43 800
and 68 800 for an additional life-year gained for BRCA1 and BRCA2, respectively. At a threshold of h20 000 per life-year gained,
implementing the US strategy in the Netherlands has a very low probability of being cost-effective. Stepping back to the less-
effective UK strategy would save relatively little in costs and results in life-years lost. When implementing the screening strategies
in the United Kingdom, the Dutch, as well as the US screening strategy have a high probability of being cost-effective.
Conclusion: From a cost-effectiveness perspective, the Dutch screening strategy is preferred for screening high-risk women in the
Netherlands as well as in the United Kingdom.
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Women with a mutation in the BRCA1 or BRCA2 gene are at an
increased lifetime breast cancer risk and they have a younger mean
age at breast cancer diagnosis than that in the general population
(mean age of onset: BRCA1, 53.9 years; BRCA2, 58.5 years; general
population, 69.5 years) (Easton et al, 1995; Ford et al, 1998; Chen
and Parmigiani 2007). These women are therefore offered
mammography screening, which, in the general population, is
the only screening test associated with reduced breast cancer
mortality (Glasziou and Houssami 2011). However, mammogra-
phy has reduced screening sensitivity in younger age groups
(Yankaskas et al, 2010) and in gene mutation carriers (Warner
et al, 2008). It has an increased risk of false-positive results at
young age (Armstrong et al, 2007), which may cause distress and
unnecessary biopsies, including surgical biopsy. It also gives an
additional risk of radiation-induced tumours, which is particularly
relevant in younger women (Preston et al, 2002; BEIR 7, 2006) and
in those with cancer susceptibility genes (Jansen-van der Weide
et al, 2010; Pijpe A et al, 2012).
The approach to overcome the above-noted limitations of
mammography screening has been to use contrast-enhanced
magnetic resonance imaging (MRI) to mammography for screen-
ing high-risk women, to increase the sensitivity of screening and to
reduce the number of mammograms (Lord et al, 2007; Warner
et al, 2008; Heijnsdijk et al, 2012). MRI has a higher sensitivity in
this context than mammography and does not use ionising
radiation. However, MRI has a variable sensitivity for ductal
carcinoma in situ, generates higher costs and has a more limited
availability and a lower specificity than mammography, which
leads to more false positives in screening (Lord et al, 2007; Warner
et al, 2008).
Recently, we published a validation study of the Simulation
Model on Radiation Risk and breast cancer Screening (SiMRiSc),
which quantified screening benefits and risks in various scenarios
for women at an increased hereditary breast cancer risk (Greuter
et al, 2010). The simulation model was shown to be valid and
suitable for the provision of accurate benefits and risks estimates
necessary for the refinement of screening guidelines in these
women. The purpose of the present study is, therefore, to evaluate
both the effectiveness and cost-effectiveness of existing breast
cancer screening strategies in which MRI and mammography are
used to screen women at an increased hereditary breast cancer risk
with this simulation model.
METHODS
Description of the simulation model for screening. We used the
SiMRiSC model (Greuter et al, 2010; Lu et al, 2012) based on
Jacobi et al (2006) and extended the model by incorporating data
on the specificity of screening, on population death rates and on
associated costs. In this micro-simulation model, women who had
a chance of developing breast cancer and of death were followed up
every year, based on probability functions. During the screening
period, breast cancers were detected by mammography and/or
MRI, based on the sensitivity of both modalities. In addition,
during the screening period, breast cancers can develop and can
clinically manifest between imaging. These are counted during the
screening period as interval cancers. When a cancer is screen-
detected or has become clinically manifested, costs of therapy and
of hospital stay are calculated (see Description of the cost model).
Women leave the simulation model when they die.
The parameters of the model. All values of the parameters that
were used in the model were derived from literature (Table 1).
The tumour induction model consisted of the mean glandular
dose for a two-view screen-film mammogram and the probability
of tumour induction from radiation (BEIR 7, 2006; Zoetelief et al,
2006). The preclinical tumour growth model consisted of the mean
and s.d. of the preclinical period based on the average tumour-
doubling time of primary breast cancers in women younger than
50 years, in women between 50 and 70 years, and in those who
were 70 years and older (Peer et al, 1993, 1996; Tilanus-Linthorst
et al, 2007). The risk of developing breast cancer during life
consisted of the baseline estimates for the lifetime risk of
developing breast cancer for BRCA1 and BRCA2 mutation carriers
(Easton et al, 1995; Ford et al, 1998). The sensitivity model
consisted of mean sensitivities for film mammography and MRI;
mean sensitivity of mammography was for five age groups (Kriege
et al, 2006; Kerlikowske et al, 2000), whereas mean sensitivity of
MRI was an overall sensitivity, as it was independent of age
(Warner et al, 2008).
The specificity model consisted of the mean specificities for each
of mammography and MRI; mean specificity of mammography
was for women younger (or older) than 40 years of age (Kriege
et al, 2006) and mean MRI specificity was an overall specificity that
was independent of age (Warner et al, 2008). The population
death-rate model consisted of the cumulative death rates at ages up
to 100 years, based on the Dutch cohort who were born in 1970
(www. statline.cbs.nl. The breast cancer death risk consisted of the
probability of death from breast cancer that was linked to the
tumour volume according to the preclinical tumour growth model
(www.cijfersoverkanker.nl).
Description of the cost model. Cost parameters included the
direct costs of screening, diagnostics, therapy and hospital stay
(Table 2). Costs of screening included that of mammography
examination and/or an MRI examination. Costs of diagnostics
included the costs of biopsy and of histopathological analysis.
Costs of therapy included costs of surgical, chemotherapeutic
endocrine and/or radiotherapeutic treatment. The costs were
estimated for the Netherlands and for United Kingdom separately.
For the calculation of the costs in the Netherlands, the unit prices
for screening, diagnostics and therapy were based on current
national tariffs and the Dutch published studies on cost prices
(www.cvz.nl; Flobbe et al, 2004; LPRM and NABON, 2000;
Farmacotherapeutisch Kompas, 2000/2001; Slotman et al, 2000;
Oostenbrink et al, 2000). For the calculation of costs in the UK
scenario, data were based on national tariffs and the UK studies on
cost prices (NICE, 2006; Prescott et al, 2007). Mean treatment costs
per patient were calculated by combining prices and treatment data
from the Dutch regional cancer registry, stratified by tumour size
(Table 3).
Validation of the model. The SiMRiSC model was validated by
comparing model-predicted outcome data with observed data from
three published large screening studies of women with an increased
hereditary breast cancer risk (Greuter et al, 2010). A sensitivity
analysis was used to estimate the error margins of model-predicted
outcome data and to analyse the sensitivity of the simulation model
to each input parameter. It was shown that the model predicted the
number of tumours reported to a high accuracy. The model was
the most sensitive to changes in the parameters related to the
lifetime breast cancer risk and the sensitivity of mammography.
Screening strategies. Three existing screening strategies were
evaluated (Table 4). The Dutch strategy uses an annual MRI
analysis for women aged 25–30 years, annual mammography and
MRI for those aged 30–60 years and a biennial mammography-
only for those aged 60–75 years (www.cbo.nl). The UK strategy
uses an annual mammography and MRI analysis for women aged
30–50 years and a mammography-only for those aged 50–70 years
for every 3 years (www.nice.org.uk). The US strategy includes an
annual mammography and MRI analysis for women aged 25 years
until the end of life, according to the American Cancer Society
guidelines and the National Comprehensive Cancer Network
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guidelines (Saslow et al, 2007; www.NCCN.org). When the strategy
in the model recommended a mammography and an MRI analysis,
these techniques were performed sequentially: first, mammography
was performed and, if positive, a screen-detected breast cancer was
counted. If the mammography was negative, an MRI was
subsequently performed.
Input population. The input population consisted of a cohort of
10 000 women followed since the age of 20 years. On the basis of
the lifetime probability function for breast cancer given the
woman’s specific gene mutation and age (Easton et al, 1995; Ford
et al, 1998), breast cancers were distributed randomly over the
simulated population each year. Each year, the age of the women
was increased, existing tumours were allowed to grow based on
age (Peer et al, 1993, 1996; Tilanus-Linthorst et al, 2007), women
died as based on a probability function (www.rivm.nl) and,
during screening, growing breast cancers could be detected by
mammography and/or MRI scanning based on the sensitivity
of both modalities and the screening strategy of the specific
country (Kerlikowske et al, 2000; Kriege et al, 2006; Yankaskas
et al, 2010).
Analysis and model output. The output of the model (Tables 5a
and b) was given in terms of the absolute number of small
tumours (diameter o2 cm) detected, the number of tumours
detected with mammography or MRI screening, the number of
Table 1. Parameters of the screening model.
Model
component
Parameter
Baseline
estimate
Mininum
estimate
Maximum
estimate
Reference
Tumour induction
due to radiation risk
Dose (mSv) 3 1 5 Peer et al (1993)
The lifetime probability of tumour induction 0.51 0.28 0.83 Preston et al (2002)
Preclinical tumour
growth
Mean preclinical period (years)
o50 years 1.9 0.63 3.17 Peer et al (1996); Tilanus-Linthorst et al
(2007); Kriege et al (2006)
50–70 years 3.7 1.23 6.17
470 years 4.5 1.50 7.50
s.d. (years)
o50 years 0.63 0.21 1.05 (Peer et al, 1996; Tilanus-Linthorst et al,
2007; Kriege et al, 2006)
50–70 years 0.51 0.17 0.85
470 years 1.06 0.35 1.77
Tumour-doubling times (days)
o50 years 80 27 133 Peer et al (1996); Tilanus-Linthorst et al
(2007); Kriege et al (2006))
50–70 years 157 52 262
470 years 188 63 313
Risk of developing
breast during life
BRCA1 probability function
Lifetime risk at age 70 years 0.80 0.71 0.84 Easton et al (1995); Ford et al (1998)
Mean age (years) 53.9 43.9 63.9
s.d. (years) 16.5 5.5 28
BRCA2 probability function
Lifetime risk at age 70 years 0.76 0.69 0.76a Easton et al (1995); Ford et al (1998)
Mean age (years) 58.5 48.5 68.5
s.d. (years) 13.8 4.6 23
Sensitivity Sensitivity of mammography at age o40 years 0.333 0.279 0.397 Kerlikowske et al (2000)
Sensitivity of mammography at age 40–49 years 0.389 0.326 0.464
Sensitivity of mammography at age 50–54 0.556 0.466 0.663
Sensitivity of mammography at age 55–59 years 0.697 0.584 0.832
Sensitivity of mammography at age X60 years 0.838 0.702 1
Sensitivity of MRI for all age groups 0.770 0.593 1 Warner et al (2008)
Specificity Specificity of mammography at age o40 years 0.961 0.924 1 Kerlikowske et al (2000)
Specificity of mammography at age X40 years 0.946 0.909 0.984
Specificity of MRI for all age groups 0.863 0.745 1 Warner et al (2008)
Death rate Average life expectancy population (years) 79 — — www.RIVM.nl
5-year survival rate breast cancer patients www.cijfersoverkanker.nl
Tumour diameter o20mm 0.98 — —
Tumour diameter 20–50mm 0.86 — —
Tumour diameter 450mm 0.62 — —
Minimum and maximum estimates correspond with two times the s.d. For a detailed description of the parameters, see Heijnsdijk et al (2012).
aThe maximum estimate is equal to the baseline estimate because the lifetime risk at the age of 100 years is 100%.
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interval cancers, the number of tumours diagnosed before the
start of screening and those after commencing the screening,
the number of mammography examinations (within the hospital
and within the National Breast Cancer Screening Program), the
number of MRI examinations and the number of false positives
for mammography and MRI. We calculated the life-years gained
by high-risk screening, the costs of this screening and the
incremental cost-effectiveness rate (ICER) defined as the ratio
of the additional costs per life-year gained, where the national
strategy was the reference. The simulation was run for the two
gene types separately. In the analyses, a discount rate of 3%
per year was applied to costs and life-years from 20 years
of age.
The simulation was carried out in the Netherlands, comparing
the three screening strategies with the Dutch population screening
as a reference, and a cost threshold of h20 000 was considered
(Habbema et al, 1989). As the population screening was the
reference and this differs over countries, in a second analysis the
simulation was carried out in the United Kingdom and the British
population screening was used as a reference. In this analysis, a
cost threshold of d25 000 was considered (National Institute for
Health and Clinical Excellence, 2007).
Sensitivity analysis. A probabilistic sensitivity analysis (PSA) was
performed for the ICER outcome. In 100 simulations, each
consisting of 1000 women, the input parameters of the model
were randomly selected from a skewed Gaussian distribution, with
a mean equal to the parameter’s baseline estimate and a negative
s.d. equal to half the difference between the mean and the
minimum estimate, and with a positive s.d. equal to half the
difference between the maximum and the mean estimate (Table 1).
On the basis of the outputs of the PSA, cost-effectiveness
acceptability curves were constructed (Matchar et al, 2005).
RESULTS
Table 5a summarises model outputs stratified for BRCA1
and BRCA2 for all three screening strategies when implemented
in the Netherlands, whereas Table 5b summarises model
outputs for all three screening strategies when implemented in
the United Kingdom. The earlier the screening started (the Dutch
and US strategies), the higher the number of small tumours
(o2 cm) that was detected (Table 5a). This effect was most
pronounced among the women with a BRCA1 or BRCA2
mutation. In addition, the earlier the screening started, the lower
the number of tumours that was diagnosed before commencing the
screening; this was most pronounced among women with a BRCA1
mutation.
The longer the screening was continued (the US strategy offers
the longest time for continuing screening), the more the tumours
were diagnosed. The longer the screening was offered, the smaller
the number of tumours that was diagnosed after stopping the
screening. More frequent MRI screens (the US strategy offers
the most frequent MRI screens) resulted in less interval cancers.
The numbers of false positives for mammography screening and
for MRI screening were highest in the US strategy and were lowest
in the UK strategy for all groups.
Table 2. Resource items for screening, diagnostics and treatment: unit prices for the Netherlands and the United Kingdom, and sources
Cost category
Unit price h
(The Netherlands) Source
Unit price d
(United Kingdom) Source/HRG code
Screening
Mammography (National Breast
Screening Program)
69 www.cvz.nl 46 www.whnt.nhs.uk
Mammography (hospital) 92 www.cvz.nl 58 NICE (2006)
MRI 227 www.cvz.nl 220 Prescott et al (2007)
Diagnostics
Pathology and evaluation 75 Flobbe et al (2004) 122 Prescott et al (2007)
Treatment
Breast conserving therapy 1009 www.cvz.nl 808 a
Mastectomy 1856 www.cvz.nl 2549 HRG J11
Radiation therapy 2891 Flobbe et al (2004); LPRM and NABON (2000);
Slotman et al (2000)
2316 a
Chemo therapy 950 Flobbe et al (2004); Slotman et al (2000) 761 a
Hormonal therapy 733 Flobbe et al (2004); Slotman et al (2000) 587 a
Specialist visits 672 Flobbe et al (2004) 538 a
Specialist visits (adjuvant therapy) 1788 Flobbe et al (2004) 1433 a
Hospital stay 1594 Flobbe et al (2004); Oostenbrink et al (2000) 1277 a
Abbreviation: HRG¼Healthcare Research Group.
aIf there was no HRG code, prices calculated were based on the balance between the per capita expenditures of the Netherlands vs that of the United Kingdom (0.84) (stats.oecd.org, visited
online: June 2012) and the conversion rate on 1 January 2009, which is 0.96 for UK pounds (www.x-rates.com visited online: June 2012).
Table 3. Mean treatment costs per patient by tumour size
p2 cm 42 cm and p5 cm 45 cm
Costs
h
Costs
d
Costs
h
Costs
d
Costs
h
Costs
d
Total therapy 4268 3909 4812 4105 5426 4789
Hospital stay 1589 1273 1573 1260 1580 1266
Total 5857 5182 6485 5365 7006 6055
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When applying the US strategy in the Netherlands, h43 800 and
68 800 should be paid for an additional life-year gained for BRCA1
and BRCA2, respectively (Table 5a). At a threshold of h20 000 per
life-year gained, implementing the US strategy in the Netherlands
has a very low probability of being cost-effective. However, if the
Dutch are willing to pay h50 000 per life-year gained, then the US
strategy has a more than 80% probability of being cost-effective
(see Figure 1A). Stepping back to the less-effective UK strategy
would save relatively little in costs and result in life-years lost. The
ICERs are a few thousand euros per life-year gained, indicating
that the Dutch strategy is cost-effective compared with the UK
strategy.
When the simulation was carried out in the United Kingdom,
the US screening strategy was somewhat more effective for
estimates of life-years gained as compared with the Dutch strategy
(Table 5b). Both the US and the Dutch screening strategy were
more effective for estimates of life-years gained as compared
with the UK strategy. When applying the Dutch strategy in the
United Kingdom, d2700 and 4900 should be paid for an additional
life-year gained for BRCA1 and BRCA2, respectively (Table 5b).
Turning to the even more intensive US strategy in the United
Kingdom would cost an additional d3400 and 6200 per life-year
gained (Table 5b). Thus, at current UK thresholds, the Dutch and
the US strategy are an extension with additional costs per QALY
that have a high (100%) probability of falling below the UK
threshold (see Figures 1B and C).
DISCUSSION
Differences between the currently recommended screening strate-
gies for women at high risk of developing breast cancer reflects the
uncertainties surrounding the optimal screening commencement
(and stopping) age, duration and frequency of screening, and the
schedule for integrating mammography and MRI screening. Using
simulation modelling, we found that the US screening strategy
showed a small increase in the number of life-years gained
Table 5a. Comparison of the Dutch screening strategy as implemented in NL
Genetic mutation BRCA1 BRCA2
Screening strategy NL UK US NL UK US
Small tumours detected (o2 cm) 750±11 663±15 799±11 777±12 696±11 821±13
Tumours detected 791±23 717±22 838±24 814±17 749±15 851±18
Interval cancers 88±11 153±12 59±6 61±5 119±9 32±5
Tumours diagnosed before start of screening 42±6 73±11 43±7 16±3 36±5 17±4
Tumours diagnosed after end of screening 26±6 30±5 N.A. 27±5 30±4 N.A.
Mammography examinations in hospital ( 1000) 18.9±0.5 15.2±0.4 24.5±0.4 21.1±0.3 16.7±0.2 27.4±0.3
Mammography examinations in NBSP ( 1000) 1.0±0.1 3.2±0.2 N.A. 1.2±0.1 3.9±0.1 N.A.
MRI examinations ( 1000) 23.2±0.5 15.1±0.2 23.9±0.3 25.6±0.3 16.6±0.1 26.8±0.3
False-positive mammographies 904±36 831±30 1.081±28 1.033±46 939±34 1.231±38
False-positive MRIs 3.139±86 2.033±48 3.231±71 3.448±38 2.249±40 3.624±74
Years of life gained (years/woman)a 1.614 1.366 1.620 1.217 1.077 1.221
Additional costs ( h1000 per woman)b 2.292 1.572 2.555 2.511 1.743 2.786
Additional costs per life-year gained compared with NL strategy
( h1000 per year per woman)
— 2.9c 43.8 — 5.5c 68.8
Abbreviations: MRI¼magnetic resonance imaging; N.A.¼not applicable; NBSP¼National Breast Cancer Screening Program; NL¼The Netherlands Comparison of the Dutch screening
strategy as implemented in NL, with the British (UK) and American (US) screening strategy when implemented in NL, assuming simultaneous application of the Dutch NBSP. Average values of
absolute numbers±s.d. per 1000 women with a BRCA1 or BRCA2 genetic mutation.
aReference is Dutch NBSP.
bAdditional costs with reference to Dutch NBSP, all cost estimates based on Dutch prices.
cSavings: programme is less expensive and adds less life-years gained with respect to the Dutch strategy.
Table 4. Evaluated screening strategies for breast cancer in women with a BRCA1/2/u mutation
Age (years) Dutch strategy UK strategy US strategy
25–30 MRI every year No screening MRI and mammography every year
30–50 MRI and mammography every year MRI and mammography every year MRI and mammography every year
50–60 MRI and mammography every year Mammography every 3 years in NBSP MRI and mammography every year
60–70 Mammography every 2 years in NBSP Mammography every 3 years in NBSP MRI and mammography every year
70–75 Mammography every 2 years in NBSP No screening MRI and mammography every year
Age over 75 when being in good health No screening No screening MRI and mammography every year
Abbreviation: NBSP¼National Breast Cancer Screening Program.
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compared with the Dutch strategy, and both the US and the Dutch
screening strategies were more effective in terms of life-years
gained compared with the UK strategy. Applying the US strategy in
the Netherlands would cost h43 800 and 68 800 for an additional
life-year gained for BRCA1 and BRCA2, respectively. The cost-
effectiveness acceptability curves confirm that the Dutch strategy
seems the most cost-effective option.
Screening BRCA1 mutation carriers was more cost-effective
than screening BRCA2 mutation carriers. This may be partly
explained by the higher lifetime risk of breast cancer in BRCA1
mutation carriers than BRCA2 mutation carriers, 0.80 and 0.76
by age 70 years, respectively, as well as the lower mean age of
onset in BRCA1 mutation carriers, 53.9 vs 58.5 years, respectively
(Chen and Parmigiani, 2007; Van der Kolk et al, 2010). Because of
the higher incidence and the lower mean age of breast cancer
among BRCA1 mutation carriers, more women with BRCA1
mutations are expected to die of breast cancer and, hence, there
may be greater potential for life-years gained by screening this
group (Kurain et al, 2010).
For BRCA1 and BRCA2 mutation carriers in the Netherlands,
the Dutch screening strategy, starting MRI-only screening at age 25
years, was most cost-effective (Table 5a). The US strategy, which
combines MRI scanning and mammography from the age of 25
years, gave only a small increase in the number of life-years gained
relative to the Dutch strategy, and a slight reduction in interval
cancers. A likely explanation for this finding is that the sensitivity
of screening mammography in women between age 25 and 30
years is relatively low, that is, 0.333 (Johnstone et al, 2001). Hence,
mammography between age 25 and 30 years does not increase
benefit over commencing with MRI-alone screening from 25–30
years (Heijnsdijk et al, 2012). The small increase in the number of
life-years gained through screening in the US strategy relative to
the Dutch strategy might also be an effect of radiation-induced
tumours; the estimated additional amount of induced breast
tumours was 0.6% (Jansen-van der Weide et al, 2010; Pijpe et al,
2012). Of note, the longer duration of screening with MRI in the
US strategy considerably increases screening costs and false-
positive screens relative to the Dutch and UK strategies, which
reduces the cost-effectiveness of screening.
The strengths of the modelling reported in this work include the
construct of model parameter values, which were mostly derived
from publications concerning women with BRCA1 or BRCA2
mutations. Furthermore, the model was applied to currently
applied guideline-based screening scenarios, and included the
effects of MRI and of X-ray tumour induction, as well as cost
analysis, to guide selection of the most cost-effective screening
strategy. Importantly, we considered costs of screening, as well as
costs of treatment (stratified for tumour size) and hospital stay,
whereas most studies on this topic limit their scope to costs of
screening. In addition, the costs included in this analysis were
based on a detailed country-specific cost study of the prices for
diagnostics and treatment of early-stage breast cancer, and a
discount rate was applied to costs and life-years.
Estimates for the costs of advanced breast cancer, including
distant metastases, diagnostics and treatment, were not included in
the current model. For this reason, we think that this model
underestimates the costs of breast cancer treatment, which will be a
problem when the model is applied to assess the overall cost-
effectiveness of the breast cancer screening in high-risk women,
rather than choosing which strategy is best. Furthermore, as the
main focus of the present paper was to study the cost-effectiveness
comparing the different strategies situated in the Netherlands or in
the United Kingdom, the US prices were not used. If the simulation
had been carried out in the United States, the fact that the per
capita health-care expenditures are about 2.05 times higher in the
United States has to be taken into account (stats.oecd.org).
Another limitation is that we did not incorporate quality-of-life
parameters that may be relevant in breast cancer screening, in line
with the work of Rijnsburger et al (2004), suggesting that there is
no loss of quality of life due to screening in high-risk women.
Although we did not consider quality-of-life parameters to be in
the scope of the present work, it represents an important topic for
Table 5b. Comparison of the UK’s screening strategy as implemented in the United Kingdom
Genetic mutation BRCA1 BRCA2
Screening strategy NL UK US NL UK US
Small tumours detected (o2 cm) 684±12 552±18 748±11 670±12 545±15 755±9
Tumours detected 731±21 624±18 781±25 715±16 618±21 781±16
Interval cancers 144±13 241±14 114±9 146±13 241±15 101±10
Tumours diagnosed before start of screening 37±8 76±8 41±7 16±4 37±6 17±4
Tumours diagnosed after end of screening 83±8 100±10 54±5 110±13 129±7 64±9
Mammography examinations in hospital ( 1000) 19.0±0.4 15.2±0.1 24.7±0.3 21.1±0.3 16.6±02 27.4±0.4
Mammography examinations in NBSP ( 1000) 0.7±0.1 2.2±0.1 N.A. 0.9±0.1 2.7±0.1 N.A.
MRI examinations ( 1000) 23.4±0.4 15.1±0.1 24.2±0.3 25.7±0.3 16.5±0.2 26.8±0.4
False-positive mammographies 909±21 778±25 1.097±21 1.015±33 871±27 1.222±33
False-positive MRIs 3.134±79 2.035±28 3.273±62 3.457±59 2.245±49 3.624±77
Years of life gained (years per woman)a 1.625 1.368 1.628 1.231 1.077 1.231
Additional costs (1000 per woman)b 2.153 1.454 2.350 2.339 1.588 2.550
Additional costs per life-year gained compared with the
UK strategy (1000 per year per woman)
2.7 — 3.4 4.9 — 6.2
Abbreviations: MRI¼magnetic resonance imaging; N.A.¼not applicable; NBSP¼National Breast Cancer Screening Program; NL¼The Netherlands. Comparison of the UK’s screening
strategy as implemented in the United Kingdom with the Dutch (NL) and American (US) screening strategy when implemented in the United Kingdom, assuming simultaneous application of the
UK NBSP. Average values of absolute numbers±s.d. per 1000 women with a BRCA1 or BRCA2 genetic mutation.
aReference is British NBSP.
bAdditional costs with reference to British NBSP, all cost estimates based on British prices.
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further research. A further limitation might be that screening vs
clinical detection was not directly but indirectly included by
assuming breast cancer mortality to be dependent on tumour
volume. In addition, the dose and the sensitivity were based on
film mammography, although current clinical practice includes
digital mammography, which has a lower dose, and digital
mammography is more accurate in women under 50 years
and in pre-menopausal women (Pisano et al, 2005) However, as
in the population screening programme most screenings are
captured on a film, we modelled the film mammography. A related
potential limitation is that additional sensitivity analyses, such as
two-way sensitivity analysis of diagnostic test performance,
were not performed. However, we learned from previous analyses
that penetrance was the most influential factor in this model
(Greuter et al, 2010); hence, analyses including a lower dose and
additional sensitivity analyses are unlikely to alter our findings. An
inherent limitation of simulation modelling is that some of the
included parameters are associated with uncertainty—in our
model, these uncertainties are predominantly determined by the
uncertainties in the lifetime risk of developing breast cancer, and
also in the preclinical growth model parameter, as indicated by the
sensitivity analysis of the main model output. As there is a lot of
international variability in the uptake of prevention strategies in
BRCA1 and BRCA2 mutation carriers, and as their effect is under
debate, this was not included in our model (Metcalfe et al, 2007;
Fakkert et al, 2012).
The strategies we evaluated for screening women with BRCA1
or BRCA2 mutations were the recommended strategies in the
Netherlands, in the United Kingdom and in the United States. As
these strategies are partly based on evidence and partly on expert
opinions, recommendations are continuously being adapted to new
data. For example, in a recent online publication supplementing
the NICE guidelines, it was proposed to intensify frequency of
mammography screening in the United Kingdom for age 50–60
years in some high-risk groups (www.icr.ac.uk). Here we have
presented information to further support tailoring screening
recommendations for women with BRCA1 and BRCA2 mutations.
In conclusion, from a cost-effectiveness perspective, the Dutch
screening strategy is preferred in the Netherlands for the screening
of high-risk women. The highly intensive US strategy does not
seem to be a cost-effective option in the Dutch situation. The less-
effective UK strategy would save relatively little in costs and result
in life-years lost.
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